Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Change in Accured Expenses for 6 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 27.59% to -$2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.3 million, a 397.09% decrease, with the full-year FY2025 number at -$6.3 million, down 397.09% from a year prior.
  • Change in Accured Expenses was -$2.8 million for Q4 2025 at Caribou Biosciences, down from -$1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q2 2024 to a low of -$4.1 million in Q1 2023.
  • A 5-year average of $290150.0 and a median of -$391000.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 411.96% in 2021, then soared 1676.44% in 2023.
  • Caribou Biosciences' Change in Accured Expenses stood at -$574000.0 in 2021, then plummeted by 60.98% to -$924000.0 in 2022, then surged by 413.31% to $2.9 million in 2023, then plummeted by 176.23% to -$2.2 million in 2024, then fell by 27.59% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Change in Accured Expenses are -$2.8 million (Q4 2025), -$1.1 million (Q3 2025), and $688000.0 (Q2 2025).